Wegovy FlexTouch Generic: When Will Generic Semaglutide Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Wegovy FlexTouch Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? 2035 to 2036 A wide window Why then?
- Has the FDA approved a generic? Not yet None in the FDA’s records yet Why not yet?
- When does the last patent end? February 2041 11 patents listed with the FDA Why is a generic expected sooner?
- Can you buy a generic today? Not yet No company lists one for sale
Generic semaglutide is expected to be available between 2035 and 2036. None is for sale yet.
Why 2035 to 2036?
The patent fight is likely to end in an agreement that sets the launch. The terms are not public yet. It is too early to rate how firm that is.
If Wegovy FlexTouch’s last patent runs to February 2041, how can a generic come sooner?
The 8 patents that run past the expected month, to February 2041 (12,569,543, 10,888,605, 11,752,198, 12,214,017 and 4 more), cover a way of using it and the product’s formulation. A patent like that protects one way of making or using the medicine, not the medicine itself. A generic company can often make its version a different way or leave that use off its label, or a court can rule the patent invalid or not infringed. Here, the companies are expected to settle on a date. Generic companies have been challenging Wegovy FlexTouch’s patents with the FDA since October 2022. That is why the expected month comes before the last protection ends. See the road to a generic
Why hasn’t the FDA approved a generic yet?
That is normal before a launch. The FDA usually can’t give a generic its final approval while a patent or exclusivity still blocks it, so final approval often comes close to the day the generic can be sold. No company holds a “tentative” approval yet either (the FDA’s word for a generic that is ready but still blocked).
Will the generic cost less?
Usually, but no company is recorded as having applied to make one yet, and a single company usually brings only a modest drop. See the price pattern
What should I do now?
Keep taking Wegovy FlexTouch as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Wegovy FlexTouch by the Numbers
- Reason
- Settlement expectedThe patent fight is likely to end in an agreement that sets the launch. The terms are not public yet.
- How sure
- Not rated Too early to rate. The month is where the records point today.
- Price competition
- None filed yet No filers on record
- Brand sales
- Sales not reported
- FDA approved 2026 June 2026 FDA Orange Book
- Patents listed 11 last runs to February 2041 A generic is expected sooner, between 2035 and 2036. See why FDA Orange Book
Wegovy FlexTouch’s Road to a Generic
Wegovy FlexTouch has had the market to itself since the FDA approved it in June 2026 (Novo Nordisk Inc). Its FDA protection (new strength) runs to March 2029. Its 11 listed patents run to February 2041 (1 already expired). Generic companies have challenged its patents with the FDA since October 2022.
The first generic of Wegovy FlexTouch is expected between 2035 and 2036.
Why that month: the patent fight is likely to end in an agreement that sets the launch. The terms are not public yet.
Why a Generic Can Come Before February 2041
The last listed patent runs to February 2041, but it covers a way of using it and the product’s formulation, not the medicine itself, which a generic can often work around or challenge. Dr. Brian explains
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Wegovy FlexTouch Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Wegovy FlexTouch’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 8,536,122 | The active ingredient; the product’s formulation | March 2026 | Expired |
| 8,129,343 | The active ingredient; the product’s formulation | December 2031 | Active |
| 9,764,003 | A way of using it (U-4418, U-3161) | June 2033 | Active |
| 12,569,543 | A way of using it (U-4443) | April 2037 | Active |
| 10,888,605 | The product’s formulation; a way of using it (U-4418, U-3162) | August 2038 | Active |
| 11,752,198 | The product’s formulation; a way of using it (U-4418, U-3162) | August 2038 | Active |
| 12,214,017 | The product’s formulation; a way of using it (U-4418, U-3162) | August 2038 | Active |
| 12,029,779 | A way of using it (U-4418, U-3162) | October 2038 | Active |
| 12,551,536 | A way of using it (U-4418) | October 2038 | Active |
| 11,478,533 | A way of using it (U-3861) | May 2040 | Active |
| 11,318,191 | The product’s formulation; a way of using it (U-4418, U-3162, U-4443, U-4560) | February 2041 | Active |
| Exclusivity | What it means | Ends | Status |
|---|---|---|---|
| New dosing D-190 | Three years of protection for a new way of dosing it. | July 2026 | Ended |
| New use I-935 | Three years of protection for a newly approved use (indication). | March 2027 | Active |
| New use I-973 | Three years of protection for a newly approved use (indication). | August 2028 | Active |
| New strength NS | Three years of protection for a new strength. | March 2029 | Active |
Source: FDA Orange Book, application 215256. Patent numbers open the patent on Google Patents.
Patent Challenges to Wegovy FlexTouch
The first patent challenge to Wegovy FlexTouch reached the FDA in October 2022, from one company on that first day. The FDA’s list has 2 entries for Wegovy FlexTouch, by form and strength. The FDA has not approved a first challenger’s generic yet.
What Is a Patent Challenge?
A generic company that wants to sell its version before Wegovy FlexTouch’s patents run out can tell the FDA that a patent is invalid, or that its version does not infringe it. The FDA calls this a “Paragraph IV certification.” The brand company usually sues, and the FDA then generally cannot approve that generic for up to 30 months while the case runs. To reward going first, the companies that challenge first can get a 180-day head start: the FDA cannot approve the generics that came after them until it ends.
| Product | First challenged | Companies that day | 180-day head start | First challenger’s generic | Challenged patents run to | |
|---|---|---|---|---|---|---|
| Approved | On sale | |||||
| Injection, 0.25 mg/0.5 mL 0.5 mg/0.5 mL 1 mg/0.5 mL 1.7 mg/0.75 mL 2.4 mg/0.75 mL | October 2022 | 1 company | No decision yet | Not yet | Not yet | February 2041 |
| Injection, 7.2 mg/0.75 mL | June 2026 | 1 company | No decision yet | Not yet | Not yet | February 2041 |
Source: the FDA’s Paragraph IV Patent Certifications list, as of September 2026. The FDA began posting the 180-day decisions and the first challenger’s approval and first sale in June 2019: an older entry it has not updated since reads “Not posted”, and “Not yet” means the list records no such event. “Companies that day” is the FDA’s count of challenges that arrived on the first day.
Who Is Lined Up to Make Generic Semaglutide
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
No company is recorded as having applied to the FDA to make a generic Wegovy FlexTouch yet.
Generic companies have challenged Wegovy FlexTouch’s patents with the FDA since October 2022: see the patent challenges.
Approved by the FDA
Not yet. The FDA has not approved a generic semaglutide. Final approval often comes close to the day a generic can be sold.
For Sale in Pharmacies
Not yet. No company lists a generic semaglutide for sale with the FDA.
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Wegovy FlexTouch Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Wegovy FlexTouch, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
Wegovy FlexTouch Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| 9.6MG/3ML (3.2MG/ML) | Solution | Subcutaneous | June 2026 | Prescription reference product |
Source: FDA Orange Book, Novo Nordisk Inc.
What a Generic Wegovy FlexTouch Means for You
Nothing Changes Until It Is in Pharmacies
Until a generic is actually for sale, keep filling Wegovy FlexTouch as usual. When one arrives, there is nothing you need to sign up for.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Wegovy FlexTouch”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.
Questions people ask about Wegovy FlexTouch
Is there a generic for Wegovy FlexTouch right now?
No. As of October 9, 2026 no generic semaglutide is listed for sale in the FDA NDC Directory.
When will Wegovy FlexTouch go generic?
2035 to 2036 is the expected window. The patent fight is likely to end in an agreement that sets the launch. The terms are not public yet. The last listed patent runs to February 2041, but it covers a way of using it and the product’s formulation, not the medicine itself, which a generic can often work around or challenge.
Will generic semaglutide be the same as Wegovy FlexTouch?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. No company is recorded as having applied to the FDA to make one yet, and a single company usually brings only a modest drop.
Has the FDA approved a generic Wegovy FlexTouch?
Not yet. The FDA Orange Book lists no approved generic version of Wegovy FlexTouch.
When does the Wegovy FlexTouch patent expire?
The FDA Orange Book lists 11 patents for Wegovy FlexTouch; the last runs to February 2041. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected window on this page (2035 to 2036) weighs all of that.
Has anyone challenged the Wegovy FlexTouch patents?
Yes. The first patent challenge to Wegovy FlexTouch reached the FDA in October 2022, from one company on that first day. The FDA has not approved a first challenger’s generic yet. A patent challenge (a “Paragraph IV certification”) is a generic company telling the FDA that a patent listed for the brand is invalid or will not be infringed by its version. The first companies to file one can earn a 180-day head start, during which the FDA cannot approve the generics that filed after them.
Changes to This Projection
- First generic expected 2035 to 2036 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- TyvasoTreprostinilDuring 2026
- HorizantGabapentin EnacarbilNovember 2026
- CotellicCobimetinibMay 2030
- MovantikNaloxegol OxalateOctober 2030
- RecarbrioCilastatin Sodium, Imipenem, and RelebactamMarch 2033
- ZulressoBrexanoloneMarch 2037
About Wegovy FlexTouch
- Generic name semaglutide
- How it is taken Injection under the skin
- Company Novo Nordisk Inc
- Hard to copy Inhalers, injectables, patches and other hard-to-copy products. Fewer companies attempt them and dates slip more often.
- Patent challenges Since October 2022 (FDA)
- More drugs Brand-name drugs starting with W
- Have a question? A pharmacist answers, free. Ask about Wegovy FlexTouch
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, FDA Paragraph IV Patent Certifications list, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.